|
AU2013267082A1
|
|
Method of treating or preventing oxidative stress-related disease
|
|
CA2852684A1
|
|
Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
|
|
WO2013010093A1
|
|
Identification of early noninvasive biomarkers for alcoholic liver disease using urinary metabolomics and the ppara-null mousei
|
|
CA2836501A1
|
|
Identification of a west nile virus cd4 t cell epitope and use thereof
|
|
MX2013012905A
|
|
Recombinant immunotoxin targeting mesothelin.
|
|
WO2012139112A1
|
|
Ubiquitin fusions for improving the efficacy of cytosolic acting targeted toxins
|
|
AU2012201689A1
|
|
MVA virus expressing modified HIV envelope, gag, and pol genes
|
|
AU2012201607A1
|
|
Methods and agents for detecting Parechovirus
|
|
WO2012112842A2
|
|
Compositions and methods for treating poliovirus
|
|
CA2822953A1
|
|
Selective detection of haemophilus influenzae
|
|
CN103328004A
|
|
Infectious hepatitis E virus genotype 3 recombinants
|
|
CN103370411A
|
|
Adenovirus serotype 26 and serotype 35 filovirus vaccines
|
|
WO2012075326A2
|
|
Treatment of inflammatory diseases by targeting the adaptor protein ciks
|
|
WO2012074683A2
|
|
Detection of adenylate cyclase
|
|
CN103596587A
|
|
Filovirus fusion proteins and their uses
|
|
WO2012054502A1
|
|
Identification of antibodies specific for lyssaviruses and methods of their use
|
|
EP2609221A2
|
|
Selective detection of neisseria meningitidis
|
|
CA2787504A1
|
|
Use of detector response curves to optimize settings for mass spectrometry
|
|
WO2012003422A1
|
|
Active adaptive detuning systems and methods for interventional devices
|
|
AU2011203056A1
|
|
A human cytotoxic T-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1
|
